Nazione: Stati Uniti
Lingua: inglese
Fonte: NLM (National Library of Medicine)
Potassium Chloride (UNII: 660YQ98I10) (Potassium Cation - UNII:295O53K152)
Padagis US LLC
Potassium Chloride
Potassium Chloride 600 mg
ORAL
PRESCRIPTION DRUG
Potassium chloride extended-release capsules are indicated for the treatment and prophylaxis of hypokalemia in adults and children with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride extended-release capsules are contraindicated in patients on amiloride or triamterene. Risk Summary There are no human data related to use of potassium chloride extended-release capsules during pregnancy and animal reproductive studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Risk Su
Potassium chloride extended-release capsules contain 600 mg and 750 mg mg of potassium chloride (equivalent to 8 mEq and 10 mEq, respectively). Table 1: How Supplied Dose Color Printing Bottle Count NDC 600 mg (8 mEq) White PAD over 0180 100 0574-0180-01 750 mg (10 mEq) White PAD over 0181 90 0574-0181-90 100 0574-0181-01 500 0574-0181-05 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature ]. Dispense in tight container. Rx only
Abbreviated New Drug Application
POTASSIUM CHLORIDE- POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE PADAGIS US LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS, USP. POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS, USP FOR ORAL USE INITIAL U.S. APPROVAL: 1948 INDICATIONS AND USAGE Potassium Chloride Extended-release Capsules, USP contain potassium chloride, a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. (1) DOSAGE AND ADMINISTRATION Monitor serum potassium and adjust dosage accordingly (2.1) If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation. (2.1) (2) _Treatment of hypokalemia:_ (2) • • _Maintenance or Prophylaxis of hypokalemia:_ (2) • • DOSAGE FORMS AND STRENGTHS • CONTRAINDICATIONS • WARNINGS AND PRECAUTIONS • ADVERSE REACTIONS Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. (6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT PERRIGO AT 1-866-634-9120 OR FDA AT 1- 800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS • • • USE IN SPECIFIC POPULATIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 5/2018 Adults: Typical doses range from 40-100 mEq/day in 2-5 divided doses; limit doses to 40 mEq per dose. (2.2) Pediatric patients: 2-4 mEq/kg/day in divided doses not to exceed 1 mEq/kg as a single dose or 20 mEq, whichever is lower; if deficits are severe or ongoing losses are great, consider intravenous therapy. (2.3) Adults: Typical dose is 20 mEq per day (2.2) Pediatric patients: Typical dose is 1 mEq/kg/day. (2.3) Extended-release capsules: 600 mg (8mEq) and 750 mg (10 mEq) Concomitant use with triamterene and Leggi il documento completo